Back to results
US 2021/0228574 A1Published application
A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
AssigneeCloudbreak Therapeutics, LLC
InventorsScott WHITCUP, Rong YANG, Jinsong NI
Life of this patent
Estimating the term…
Abstract
A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an α adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating α adrenergic receptor of the patient with an agonist of the receptor.
Claims16
A composition for use in the treatment of ocular hyperemia,
- wherein the composition comprises an anti-angiogenic agent and an α adrenergic receptor agonist.
A method for treating ocular hyperemia for a patient comprising:
- inhibiting a plurality of kinase receptors of the patient with an MKI, and
- activating α adrenergic receptors of the patient with an agonist of the receptor,
- wherein the kinase receptors are selected from the group consisting of VEGFR 1, 2, and 3, and PDGFR α, β, and Lyn, and preferably VEGFR1, 2, or 3.
Dependencies are inferred from the claim text.